4583.T
Chiome Bioscience Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 82.00
+1.23%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 602.0M | 593.0M | 780.0M | 682.0M | 630.0M |
| Cost of Revenue | 66.6M | 237.7M | 348.0M | 283.9M | 282.0M |
| Gross Profit | 80.5M | 355.6M | 432.9M | 398.6M | 348.9M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 312.9M | 1.3B | 1.5B | 1.6B | 1.6B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 312.9M | 1.3B | 1.5B | 1.6B | 1.6B |
| Cost and Expenses | 1.5B | 1.6B | 1.8B | 1.9B | 1.9B |
| Operating Income (EBIT) | (947.0M) | (979.0M) | (1.0B) | (1.2B) | (1.3B) |
| Non-Operating | |||||
| Interest Income | 1.0M | 2.5M | 215.0K | 19.0K | 21.0K |
| Interest Expense | 292.0K | 3.2M | 2.9M | 2.1M | 1.3M |
| Net Interest Income | 739.0K | (697.0K) | (2.6M) | (2.0M) | (1.3M) |
| Other Non-Op Income/Expense | 6.0K | (9.4M) | 11.7M | (12.1M) | 14.8M |
| Non-Operating Income (excl Interest) | 284.0K | 143.0K | 29.8M | 1.1M | 20.5M |
| EBT (Pre-Tax Income) | (232.3M) | (979.5M) | (1.0B) | (1.2B) | (1.2B) |
| Income Tax Expense | 810.0K | 3.2M | 3.2M | 5.0M | 5.0M |
| Bottom Line | |||||
| Net Income | (949.0M) | (982.0M) | (1.0B) | (1.2B) | (1.2B) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (949.0M) | (982.0M) | (1.0B) | (1.2B) | (1.2B) |
| Per Share | |||||
| Basic EPS | (¥14) | (¥14) | (¥18) | (¥25) | (¥28) |
| Diluted EPS | (¥14) | (¥14) | — | — | — |
| Revenue Per Share | ¥9 | ¥9 | ¥13 | ¥14 | ¥14 |
| Shares | |||||
| Basic Shares Outstanding | 70.4M | 67.9M | 58.2M | 49.5M | 44.0M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | (975.3M) | (1.0B) | (1.2B) | (1.3B) |
| D&A | — | 3.7M | 1.2M | 1.2M | 1.5M |
| EBIT | (947.0M) | (979.0M) | (1.0B) | (1.2B) | (1.3B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026